JP2018522880A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522880A5
JP2018522880A5 JP2017568234A JP2017568234A JP2018522880A5 JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5 JP 2017568234 A JP2017568234 A JP 2017568234A JP 2017568234 A JP2017568234 A JP 2017568234A JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5
Authority
JP
Japan
Prior art keywords
cancer
dengue virus
denv
composition according
pfu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040787 external-priority patent/WO2017004567A1/en
Publication of JP2018522880A publication Critical patent/JP2018522880A/ja
Publication of JP2018522880A5 publication Critical patent/JP2018522880A5/ja
Priority to JP2021113634A priority Critical patent/JP2021176862A/ja
Pending legal-status Critical Current

Links

JP2017568234A 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法 Pending JP2018522880A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021113634A JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562231351P 2015-07-02 2015-07-02
US62/231,351 2015-07-02
PCT/US2016/040787 WO2017004567A1 (en) 2015-07-02 2016-07-01 Compositions and methods for combination therapy with dengue virus and dendritic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021113634A Division JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2018522880A JP2018522880A (ja) 2018-08-16
JP2018522880A5 true JP2018522880A5 (cg-RX-API-DMAC7.html) 2019-08-08

Family

ID=57609586

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568234A Pending JP2018522880A (ja) 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Country Status (8)

Country Link
US (6) US9730989B2 (cg-RX-API-DMAC7.html)
EP (1) EP3316897A4 (cg-RX-API-DMAC7.html)
JP (2) JP2018522880A (cg-RX-API-DMAC7.html)
CN (1) CN107921063A (cg-RX-API-DMAC7.html)
CA (1) CA2991212A1 (cg-RX-API-DMAC7.html)
DE (1) DE202016008300U1 (cg-RX-API-DMAC7.html)
MX (1) MX2018000052A (cg-RX-API-DMAC7.html)
WO (1) WO2017004567A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522880A (ja) 2015-07-02 2018-08-16 プライムヴァックス イミュノ−オンコロジー，インク． デングウイルス及び樹状細胞による併用療法のための組成物及び方法
MX2018003757A (es) * 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
CA3082779A1 (en) * 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
AU2018283957B2 (en) * 2017-06-12 2024-01-25 Cleveland Clinic Lerner Research Institute ZIKA virus strains for treatment of glioblastoma
CN110996997A (zh) * 2017-06-15 2020-04-10 普莱瓦克斯免疫肿瘤学公司 采用登革病毒和树突细胞进行癌症治疗的组合物和方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015972A (en) 1905-09-25 1912-01-30 Westinghouse Electric & Mfg Co Electric switch.
US1035755A (en) 1908-07-21 1912-08-13 Glenn S Smith Draftsman's apparatus.
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
EP1056834A2 (en) * 1998-02-20 2000-12-06 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US6524587B1 (en) 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
US6048686A (en) 1998-05-05 2000-04-11 Randy Kyle Brown Hyperthermia and immunotherapy for cancer
EP1165128A2 (en) * 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-2 virus vaccine
EP1165127B1 (en) 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
AU4183100A (en) 1999-03-31 2000-10-16 University Of Pittsburgh (in vitro) induction of antigen-specific t-cells using dendritic cell-tumor cellor dendritic cell-viral cell derived immunogens
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
AU2005257107A1 (en) 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
CA2602434C (en) * 2005-04-08 2016-06-07 Argos Therapeutics, Inc. Dendritic cell compositions and methods
US8337860B2 (en) 2006-08-15 2012-12-25 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Development of dengue virus vaccine components
WO2008039969A2 (en) * 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2013188315A1 (en) * 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
CA2793458A1 (en) 2010-03-15 2011-09-22 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
CN103619349A (zh) 2011-05-26 2014-03-05 葛兰素史密丝克莱恩生物有限公司 灭活登革热病毒疫苗
EP2543386A1 (en) * 2011-07-05 2013-01-09 Sotio a.s. Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
EP3542816A1 (en) 2014-02-14 2019-09-25 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
JP7570080B2 (ja) 2015-05-07 2024-10-21 ベイラー カレッジ オブ メディスン 樹状細胞免疫療法
JP2018522880A (ja) * 2015-07-02 2018-08-16 プライムヴァックス イミュノ−オンコロジー，インク． デングウイルス及び樹状細胞による併用療法のための組成物及び方法
MX2018003757A (es) 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
CA3082779A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
CN110996997A (zh) 2017-06-15 2020-04-10 普莱瓦克斯免疫肿瘤学公司 采用登革病毒和树突细胞进行癌症治疗的组合物和方法

Similar Documents

Publication Publication Date Title
JP2018522880A5 (cg-RX-API-DMAC7.html)
JP2016531927A5 (cg-RX-API-DMAC7.html)
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
WO2015193359A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
MA39907A (fr) Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
WO2015013461A3 (en) Cancer vaccination with antigen evolution
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
GB0700058D0 (en) Anti-tumor vaccine based on normal cells
NZ711946A (en) Newcastle disease viruses and uses thereof
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX379423B (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
MX376066B (es) Anticuerpos dirigidos contra cd127.
WO2013120012A3 (en) Cdim binding proteins and uses thereof
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
WO2018083220A3 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
RU2014117707A (ru) Способ лечения пролиферативного заболевания
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
MX2021003826A (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
MX385304B (es) Nuevos complejos metálicos de nocardamina y su uso en composiciones farmacéuticas.
WO2017041092A3 (en) Anti-survivin antibodies for cancer therapy